Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Upamostat · WX-671

Small molecule · developed by RedHill Biopharma

Phase 2/3 Most advanced trial (none active)
RDHL Developer
1 Registered trials

What is Upamostat?

Upamostat (WX-671) is an orally administered capsule formulation of 200 mg per capsule. It is studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
WX-671
Drug type
Small molecule
Therapy area
Infectious disease
Developer
RedHill Biopharma Limited (RDHL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
S5M7KW6U17

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04723537 Phase 2/3 Covid19 Terminated RDHL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19

More from RedHill Biopharma

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RDHL page.

Follow RDHL, the company behind Upamostat

See RDHL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RDHL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.